STAT's weekly 'Up and down the ladder' column highlights notable executive appointments and career moves across the pharmaceutical and biotechnology industries.In this edition, the featured announcement is that Delphia Therapeutics has appointed David Kerstein as its new chief medical officer.

Kerstein brings previous experience in the same leadership role at IDRx and Theseus Pharmaceuticals, adding significant clinical development and biotechnology expertise to Delphia's executive team.

The column also invites pharmaceutical and biotech companies to submit information about new hires, promotions, and other staffing changes for inclusion in future editions, emphasizing its role as a recurring industry personnel roundup.

Most of the article beyond the introductory announcement is available only to STAT+ subscribers, limiting access to the complete list of executive moves covered in this week's feature.

The piece is authored by Ed Silverman, Pharmalot columnist and senior writer at STAT, who regularly reports on pharmaceutical industry developments, including drug pricing, access, patents, litigation, and corporate news.

Although only the opening section is publicly visible, the article serves as a recurring resource for tracking leadership changes across the life sciences sector, providing visibility into executive appointments that may influence company strategy, research, clinical development, and business operations throughout the pharmaceutical and biotechnology sectors.